Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer

Vered Stearns, C. Alexander Ewing, Rebecca Slack, Marie F. Penannen, Daniel F. Hayes, Theodore N. Tsangaris

Research output: Contribution to journalArticle

Abstract

Background: After neoadjuvant chemotherapy, women with locally advanced breast cancer (LABC) undergo a modified radical mastectomy or lumpectomy with axillary lymph node dissection (ALND) and radiotherapy. Sentinel lymphadenectomy (SL) is accepted for axillary evaluation in early breast cancer. We assessed the feasibility and predictive value of SL after neoadjuvant chemotherapy. Methods: Eligible women received neoadjuvant therapy for LABC and were scheduled to undergo a definitive surgical procedure. Vital blue dye SL was attempted followed by level I and II axillary dissection. Results: SL was successful in 29 of 34 patients (detection rate, 85%). Thirteen patients (45%) had positive nodes, and eight (28%) had negative nodes on both SL and ALND. In five patients (17%), the sentinel node was the only positive node identified. Overall, there was a 90% concordance between SL and ALND. The false-negative rate and negative predictive value were 14% and 73%, respectively. Among the subgroup without inflammatory cancer, the detection and concordance rates were 89% and 96%, respectively. The false-negative rate was 6%, and the negative predictive value was 88%. Conclusions: SL after neoadjuvant chemotherapy may reliably predict axillary staging except in inflammatory breast cancer. Further studies are required to assess the utility of SL as the only mode of axillary evaluation in these women.

Original languageEnglish (US)
Pages (from-to)235-242
Number of pages8
JournalAnnals of Surgical Oncology
Volume9
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Inflammatory Breast Neoplasms
Axilla
Lymph Node Excision
Breast Neoplasms
Drug Therapy
cyhalothrin
Modified Radical Mastectomy
Neoadjuvant Therapy
Segmental Mastectomy
Dissection

Keywords

  • Inflammatory breast cancer
  • Locally advanced breast cancer
  • Neoadjuvant chemotherapy
  • Sentinel lymph node mapping
  • Sentinel lymphadenectomy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. / Stearns, Vered; Alexander Ewing, C.; Slack, Rebecca; Penannen, Marie F.; Hayes, Daniel F.; Tsangaris, Theodore N.

In: Annals of Surgical Oncology, Vol. 9, No. 3, 2002, p. 235-242.

Research output: Contribution to journalArticle

Stearns, Vered ; Alexander Ewing, C. ; Slack, Rebecca ; Penannen, Marie F. ; Hayes, Daniel F. ; Tsangaris, Theodore N. / Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. In: Annals of Surgical Oncology. 2002 ; Vol. 9, No. 3. pp. 235-242.
@article{1fda705f906e46c98b1b79d2dd028853,
title = "Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer",
abstract = "Background: After neoadjuvant chemotherapy, women with locally advanced breast cancer (LABC) undergo a modified radical mastectomy or lumpectomy with axillary lymph node dissection (ALND) and radiotherapy. Sentinel lymphadenectomy (SL) is accepted for axillary evaluation in early breast cancer. We assessed the feasibility and predictive value of SL after neoadjuvant chemotherapy. Methods: Eligible women received neoadjuvant therapy for LABC and were scheduled to undergo a definitive surgical procedure. Vital blue dye SL was attempted followed by level I and II axillary dissection. Results: SL was successful in 29 of 34 patients (detection rate, 85{\%}). Thirteen patients (45{\%}) had positive nodes, and eight (28{\%}) had negative nodes on both SL and ALND. In five patients (17{\%}), the sentinel node was the only positive node identified. Overall, there was a 90{\%} concordance between SL and ALND. The false-negative rate and negative predictive value were 14{\%} and 73{\%}, respectively. Among the subgroup without inflammatory cancer, the detection and concordance rates were 89{\%} and 96{\%}, respectively. The false-negative rate was 6{\%}, and the negative predictive value was 88{\%}. Conclusions: SL after neoadjuvant chemotherapy may reliably predict axillary staging except in inflammatory breast cancer. Further studies are required to assess the utility of SL as the only mode of axillary evaluation in these women.",
keywords = "Inflammatory breast cancer, Locally advanced breast cancer, Neoadjuvant chemotherapy, Sentinel lymph node mapping, Sentinel lymphadenectomy",
author = "Vered Stearns and {Alexander Ewing}, C. and Rebecca Slack and Penannen, {Marie F.} and Hayes, {Daniel F.} and Tsangaris, {Theodore N.}",
year = "2002",
doi = "10.1245/aso.2002.9.3.235",
language = "English (US)",
volume = "9",
pages = "235--242",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer

AU - Stearns, Vered

AU - Alexander Ewing, C.

AU - Slack, Rebecca

AU - Penannen, Marie F.

AU - Hayes, Daniel F.

AU - Tsangaris, Theodore N.

PY - 2002

Y1 - 2002

N2 - Background: After neoadjuvant chemotherapy, women with locally advanced breast cancer (LABC) undergo a modified radical mastectomy or lumpectomy with axillary lymph node dissection (ALND) and radiotherapy. Sentinel lymphadenectomy (SL) is accepted for axillary evaluation in early breast cancer. We assessed the feasibility and predictive value of SL after neoadjuvant chemotherapy. Methods: Eligible women received neoadjuvant therapy for LABC and were scheduled to undergo a definitive surgical procedure. Vital blue dye SL was attempted followed by level I and II axillary dissection. Results: SL was successful in 29 of 34 patients (detection rate, 85%). Thirteen patients (45%) had positive nodes, and eight (28%) had negative nodes on both SL and ALND. In five patients (17%), the sentinel node was the only positive node identified. Overall, there was a 90% concordance between SL and ALND. The false-negative rate and negative predictive value were 14% and 73%, respectively. Among the subgroup without inflammatory cancer, the detection and concordance rates were 89% and 96%, respectively. The false-negative rate was 6%, and the negative predictive value was 88%. Conclusions: SL after neoadjuvant chemotherapy may reliably predict axillary staging except in inflammatory breast cancer. Further studies are required to assess the utility of SL as the only mode of axillary evaluation in these women.

AB - Background: After neoadjuvant chemotherapy, women with locally advanced breast cancer (LABC) undergo a modified radical mastectomy or lumpectomy with axillary lymph node dissection (ALND) and radiotherapy. Sentinel lymphadenectomy (SL) is accepted for axillary evaluation in early breast cancer. We assessed the feasibility and predictive value of SL after neoadjuvant chemotherapy. Methods: Eligible women received neoadjuvant therapy for LABC and were scheduled to undergo a definitive surgical procedure. Vital blue dye SL was attempted followed by level I and II axillary dissection. Results: SL was successful in 29 of 34 patients (detection rate, 85%). Thirteen patients (45%) had positive nodes, and eight (28%) had negative nodes on both SL and ALND. In five patients (17%), the sentinel node was the only positive node identified. Overall, there was a 90% concordance between SL and ALND. The false-negative rate and negative predictive value were 14% and 73%, respectively. Among the subgroup without inflammatory cancer, the detection and concordance rates were 89% and 96%, respectively. The false-negative rate was 6%, and the negative predictive value was 88%. Conclusions: SL after neoadjuvant chemotherapy may reliably predict axillary staging except in inflammatory breast cancer. Further studies are required to assess the utility of SL as the only mode of axillary evaluation in these women.

KW - Inflammatory breast cancer

KW - Locally advanced breast cancer

KW - Neoadjuvant chemotherapy

KW - Sentinel lymph node mapping

KW - Sentinel lymphadenectomy

UR - http://www.scopus.com/inward/record.url?scp=0036214547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036214547&partnerID=8YFLogxK

U2 - 10.1245/aso.2002.9.3.235

DO - 10.1245/aso.2002.9.3.235

M3 - Article

VL - 9

SP - 235

EP - 242

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 3

ER -